Delivering on the promise of RNA therapeutics
We use innovative and proprietary bioabsorbable silicon-based Bio-Courier® technology to facilitate superior delivery of nucleic acids for a wide range of targets and indications.
We are headquartered in Guildford, England with fully integrated state-of-the-art research labs, pilot manufacturing and bioanalytical facilities.
SiSaf is an RNA delivery and therapeutics company.
Our proprietary Bio-Courier® technology addresses the limitations of other RNA delivery technologies through the hybridization of organic materials with inorganic bioabsorbable silicon.
Our Pipeline
SiSaf is developing a growing pipeline of RNA therapeutics that utilize the delivery capabilities of Bio-Courier® technology.
Pancreatic Cancer
A novel miRNA-based treatment approach for solid tumors, with pancreatic ductal adenocarcinoma being the initial indication.
Metastatic Cancer
A siRNA-based treatment that targets a critical pathway in tumor metastasis.
Osteopetrosis ADO2
A siRNA-based therapy for autosomal dominant Osteopetrosis Type II, a rare skeletal disease also known as marble bone disease.
Our Enabling Technology
Unlike conventional lipid nanoparticles, Bio-Courier particles can be manufactured empty and loaded with the RNA later, at the desired point and time of use.
Not only does this enable local manufacturing but there is no need for an ultra-cold supply chain.
In The News
Crossing the Cell Membrane Without Viruses
May 14, 2025
Promising Results in Phase 2 Trial of ProSilic
June 10, 2024
mRNA Revolution: A new generation of medicine. SiSaf case study
October 4, 2023
Delivering a New "Post-Covid" Generation of RNA Therapeutics
October 14, 2022
SiSaf Ltd Announces US$13.2 Million Series B Financing
November 20, 2020
SiSaf Establishes Strategic Partnership with Avellino Labs
December 18, 2019
